Europska Unija - islandski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - entecavir einhýdrat - lifrarbólga b - veirueyðandi lyf til almennrar notkunar - entecavir mylan is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. alvarleg lifrarsjúkdóm. fyrir bæði bætt og alvarleg lifrarsjúkdóm, þetta vísbending er byggt á rannsókn gögn í núkleósíð barnaleg sjúklinga með hbeag jákvæð og hbeag neikvæð hbv sýkingu. með tilliti til sjúklinga með lifrarbólgu b sem eru með lamivúdín. entecavir mylan er einnig ætlað til meðferð langvarandi hbv sýkingu í núkleósíð barnaleg börn sjúklingar frá 2 til.

Europska Unija - islandski - EMA (European Medicines Agency)

cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - Ónæmisfræðilegar upplýsingar - sheep; cattle - sheepactive bólusetningar gegn bluetongue veira serotype 8 til að koma í veg fyrir viraemia og til að draga úr klínískum merki. upphaf ónæmis: 20 dagar eftir annan skammt. lengd ónæmis: 1 ár eftir annan skammt. cattleactive bólusetningar gegn bluetongue veira serotype 8 til að koma í veg fyrir viraemia. upphaf ónæmis: 31 dagar eftir annan skammt. lengd ónæmis: 1 ár eftir annan skammt.

Europska Unija - islandski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - bluetongue-virus serotype-1 antigen, bluetongue virus serotype 8 antigen - Ónæmisfræðilegar upplýsingar - sheep; cattle - sheepactive bólusetningar af kindum og naut til að koma í veg fyrir viraemia og til að draga úr klínískum merki af völdum bluetongue veira serotypes 1, 2, 4 og/ eða 8 (sambland af hámarks 2 serotypes), virk bólusetningar af kindum og naut til að koma í veg fyrir viraemia og til að draga úr klínískum merki af völdum bluetongue veira serotypes 1,2, 4 og/ eða 8 (sambland af hámarks 2 serotypes), virk bólusetningar sauðfé til að koma í veg fyrir viraemia og til að draga úr klínískum merki af völdum bluetongue veira serotypes 1, 2, 4 og/eða 8 (sambland af hámarks 2 serotypes). cattleactive bólusetningar af nautgripum til að koma í veg fyrir viraemia af völdum bluetongue veira serotype 1, 2, 4 og/ eða 8, og til að draga úr klínískum merki af völdum bluetongue veira serotypes þegar fram í þessa tegund: serotype 1, 4 og / eða 8 (sambland af hámarks 2 serotypes). virk bólusetningar af nautgripum til að koma í veg fyrir viraemia af völdum bluetongue veira serotype 1, 2, 4 og/ eða 8, og til að draga úr klínískum merki af völdum bluetongue veira serotypes þegar fram í þessa tegund: serotype 1, 4 og / eða 8 (sambland af hámarks 2 serotypes). virk bólusetningar af kindum og naut til að koma í veg fyrir viraemia og til að draga úr klínískum merki af völdum bluetongue veira serotypes 1, 2, 4 og/eða 8 (sambland af hámarks 2 serotypes).

Europska Unija - islandski - EMA (European Medicines Agency)

bavarian nordic a/s - breytt bóluefni ankara - bavarian nordic (mva-bn) veira - smallpox vaccine; monkeypox virus - Önnur veiru bóluefni, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 og 5. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Europska Unija - islandski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - Ónæmislyf fyrir felidae, - kettir - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europska Unija - islandski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - Ónæmislyf fyrir felidae, - kettir - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Europska Unija - islandski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - Ónæmislyf fyrir felidae, - kettir - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europska Unija - islandski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - Ónæmislyf fyrir felidae, - kettir - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. sýnt hefur verið fram á ónæmiskerfi einum viku eftir grunnbólusetningu fyrir rinotracheitis, calicivirus, chlamydophila felis og panleucopenia þætti. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europska Unija - islandski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - Ónæmislyf fyrir felidae, - kettir - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europska Unija - islandski - EMA (European Medicines Agency)

zoetis belgium - óvirkja blátunguveiru, sermigerð 8, stofnbtv-8 / bel2006 / 02 - Ónæmisfræðilegar upplýsingar - nautgripir - active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.